VUB08_MFS	
    			    			
                VUBe008-A            
            
        General
Cell Line | 
					|
| hPSCreg name | VUBe008-A | 
| Cite as: | VUBe008-A (RRID:CVCL_9845) | 
| Alternative name(s) | 
									 
	VUB08_MFS	 
							 | 
						
| Cell line type | Human embryonic stem cell (hESC) | 
| Similar lines | 
							 ISMMSi002-B (MFS60-3-1, SAMEA104276575) Donor's gene variants: FBN1, FBN1 Donor diseases: Marfan syndrome  | 
					
| Last update | 15th October 2021 | 
| User feedback | |
Provider | 
					|
| Generator | Vrije Universiteit Brussel (VUB) | 
| Derivation country | Belgium | 
External Databases | 
						|
| Cellosaurus | CVCL_9845 | 
| Wikidata | Q54993393 | 
							    
							General Information | 
					|
| Publications | 
  | 
    						
| * Is the cell line readily obtainable for third parties? | 
                                     Yes                                                                      | 
                            
Donor Information
General Donor Information | 
					|
| Sex | female | 
Phenotype and Disease related information (Donor) | 
					|
| Diseases | A disease was diagnosed.
																	 | 
					
Ethics
| Was the embryo established purely for research purposes? | No | 
| Have both parents consented to the use of the embryo for ESC derivation? | Yes | 
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes | 
| Was the consent voluntarily given? | Yes | 
| Alternatives to consent are available? | Yes | 
| Alternatives to consent | |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised | 
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes | 
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No | 
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No | 
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes | 
| Name of accrediting authority involved? | Federal Commission Medical and Scientific Research on embryos in vitro (Belgium) | 
| Approval number | 
hESC Derivation
| Date of derivation | 2006-01-14 | 
						
| Embryo stage | Blastula with ICM and Trophoblast | 
| Supernumerary embryos from IVF treatment? | 
								 No 
								
																											
											Other hESC source:
											IVF										 
																								 | 
						
| PGD Embryo? | 
								 Yes 							 | 
						
| ZP removal technique | Spontaneous Hatching | 
| Cell isolation | Immunosurgery | 
| Cell seeding | Isolated ICM | 
Culture Conditions
| Surface coating | MEF | |||||||||
| Feeder cells | 
																								mouse embryonic fibroblast cell Cellfinder Ont Id: EFO_0004040  | 
						|||||||||
| O2 Concentration | 20 % | |||||||||
| CO2 Concentration | 10 % | |||||||||
| Medium | 
								Other medium:		 
			Base medium: Knockout-DMEM			 
				
				Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements 
				
  | 
						
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles | 
| Alkaline Phosphatase | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                ||||
| SSEA-1 | 
											 No 						                 | 
																                
						                
						                	 | 
						                ||||
| SSEA-3 | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                ||||
| SSEA-4 | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                ||||
| TRA 1-60 | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                ||||
| TRA 1-81 | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                ||||
| DNMT3B | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| GDF3 | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| LIN28 | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| NANOG | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| NPM1 | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| POU5F1 (OCT-4) | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| ZFP42 (REX-1) | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| SOX2 | 
											 Yes 						                 | 
																                
						                
							                 | 
						                
Differentiation Potency
Genotyping
Karyotyping (Cell Line) | 
					|
| Has the cell line karyotype been analysed? | 
								 Yes 								
																	
												46XX
											 
																				
																															
											Passage number: 42											 
																													 | 
						
Other Genotyping (Cell Line) | 
					|

Login to share your feedback, experiences or results with the research community.